Should you buy West Pharmaceutical Services, I (WST)?
Updated
West Pharmaceutical Services is a healthcare components manufacturer with a perfect Piotroski F-Score of 9/9, a wide economic moat, four consecutive earnings beats averaging 18.2% above estimates, and strong revenue growth of 21% — though its current price has reached the prior analyst target, making near-term entry timing unfavorable.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
West Pharmaceutical carries a perfect Piotroski F-Score of 9 out of 9, a wide economic moat rating, and strong operating margins of 17%, marking it as a compounder-quality business with durable competitive advantages in pharmaceutical packaging. Quality breakdown | Piotroski F-Score remains at 8 or above and operating margins stay above 15% over the next 12 months. | →Stable |
| CounterWide moat assessments in healthcare components can erode if pharmaceutical manufacturers consolidate purchasing or bring packaging in-house, reducing West Pharma's pricing power. | ||
West Pharmaceutical has beaten earnings estimates in each of the last four quarters with an average surprise of 18.2%, most recently delivering a 27.1% beat in April 2026. Earnings | The beat streak continues for at least 3 of the next 4 quarters with average surprise remaining above 10%. | →Stable |
| CounterA 27.1% beat in the most recent quarter may set a high baseline expectation that is difficult to sustain, compressing future surprise potential. | ||
Revenue growth of 21% year-over-year and strong earnings growth place West Pharmaceutical among the industry growth leaders in its peer group, supported by a Piotroski-validated balance sheet. Growth breakdown | Revenue growth remains above 12% annually and earnings growth stays above 15% over the next 12 months. | →Stable |
| Counter21% revenue growth may reflect post-pandemic pharmaceutical restocking that normalizes lower, making current growth rates misleading as a baseline for forward projections. | ||
West Pharmaceutical carries a perfect Piotroski F-Score of 9 out of 9, a wide economic moat rating, and strong operating margins of 17%, marking it as a compounder-quality business with durable competitive advantages in pharmaceutical packaging.
→Stable- Expectation
- Piotroski F-Score remains at 8 or above and operating margins stay above 15% over the next 12 months.
CounterWide moat assessments in healthcare components can erode if pharmaceutical manufacturers consolidate purchasing or bring packaging in-house, reducing West Pharma's pricing power.
West Pharmaceutical has beaten earnings estimates in each of the last four quarters with an average surprise of 18.2%, most recently delivering a 27.1% beat in April 2026.
→Stable- Expectation
- The beat streak continues for at least 3 of the next 4 quarters with average surprise remaining above 10%.
CounterA 27.1% beat in the most recent quarter may set a high baseline expectation that is difficult to sustain, compressing future surprise potential.
Revenue growth of 21% year-over-year and strong earnings growth place West Pharmaceutical among the industry growth leaders in its peer group, supported by a Piotroski-validated balance sheet.
→Stable- Expectation
- Revenue growth remains above 12% annually and earnings growth stays above 15% over the next 12 months.
Counter21% revenue growth may reflect post-pandemic pharmaceutical restocking that normalizes lower, making current growth rates misleading as a baseline for forward projections.
▸ Show 1 more pillar▾ Show fewer
Dependence on single-source raw material suppliers creates a supply chain concentration risk that could disrupt production and cause cost spikes if a key supplier experiences capacity constraints or quality failures.
→Stable- Expectation
- No production disruptions attributable to single-source supply failures are reported over the next 12 months.
CounterSingle-source supply arrangements are often accompanied by long-term contracts and strategic supplier relationships that reduce disruption probability relative to spot-market procurement.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1West Pharmaceutical carries a perfect Piotroski F-Score of 9 out of 9, a wide economic moat rating, and strong operating margins of 17%, marking it as a compounder-quality business with durable competitive advantages in pharmaceutical packaging.
Trip ifPiotroski F-Score falls below 7, declining more than 2 points from the perfect score of 9 out of 9.
- P2West Pharmaceutical has beaten earnings estimates in each of the last four quarters with an average surprise of 18.2%, most recently delivering a 27.1% beat in April 2026.
Trip ifAverage earnings surprise falls below 5% in at least 2 of the next 4 reported quarters.
- P3Revenue growth of 21% year-over-year and strong earnings growth place West Pharmaceutical among the industry growth leaders in its peer group, supported by a Piotroski-validated balance sheet.
Trip ifRevenue growth falls below 8% year-over-year, declining more than 13 percentage points from the current 21%.
- P4Dependence on single-source raw material suppliers creates a supply chain concentration risk that could disrupt production and cause cost spikes if a key supplier experiences capacity constraints or quality failures.
Trip ifPrice drops below $290.73, reaching the stop-loss level and falling more than 12% below the current $331.43.
How the engine reached this verdict
TrendMatrix's engine output for West Pharmaceutical Services, I (WST) is HOLD_IF_HOLDING with medium conviction, score 6.1/10 at $349.58. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
On the bull side: Strong earnings beat streak (4/4); High-quality business; Strong growth profile. On the bear side: Concentration risk — Supplier: single-source raw materials; Concentration risk — Geographic: international sales (56.7%); Analyst target reached - limited upside remaining. Active engine warnings: V8: Target reached (-10.9% upside), V9 Gate Failed: ASYMMETRY:-0.9=NEGATIVE.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $334.09 for existing positions. Asymmetric R:R is -0.33, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
HOLD flips toward BUY_WAIT if reward-to-risk (NEGATIVE) clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates WST — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸High-quality business
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Supplier: single-source raw materials
- ▸Concentration risk — Geographic: international sales (56.7%)
- ▸Analyst target reached - limited upside remaining